Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Enterprise Value (2016 - 2025)

Rein Therapeutics filings provide 10 years of Enterprise Value readings, the most recent being -$3.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 75.01% year-over-year to -$3.2 million, compared with a TTM value of -$3.2 million through Dec 2025, up 75.01%, and an annual FY2025 reading of -$3.2 million, up 75.01% over the prior year.
  • Enterprise Value hit -$3.2 million in Q4 2025 for Rein Therapeutics, up from -$4.0 million in the prior quarter.
  • The five-year high for Enterprise Value was -$3.2 million in Q4 2025, with the low at -$52.2 million in Q3 2021.
  • Median Enterprise Value over the past 5 years was -$12.5 million (2023), compared with a mean of -$15.7 million.
  • The sharpest move saw Enterprise Value tumbled 485.99% in 2022, then skyrocketed 79.49% in 2023.
  • Year by year, Enterprise Value stood at -$3.6 million in 2021, then plummeted by 485.99% to -$21.2 million in 2022, then rose by 18.26% to -$17.4 million in 2023, then increased by 25.91% to -$12.9 million in 2024, then surged by 75.01% to -$3.2 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$3.2 million, -$4.0 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.